MedicaidPrior AuthMedium impact
Parsabiv® (etelcalcetide) intravenous solution (Revised)
Humana·KY, SC, VA · Nephrology, Endocrinology·Medicaid
Effective date
Jul 1, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicaid has updated prior authorization requirements for Parsabiv (etelcalcetide) injection for secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis. This affects Medicaid patients in Kentucky, South Carolina, and Virginia, with specific clinical criteria including age ≥18, corrected serum calcium ≥8.3 mg/dL, and previous treatment with generic vitamin D analogs.
Action Required
By July 1, 2025: Billing team must ensure prior authorization is obtained for all Parsabiv (etelcalcetide) prescriptions for Medicaid patients from Kentucky, South Carolina, and Virginia. Verify patient meets all criteria: age ≥18, secondary hyperparathyroidism due to CKD, currently on hemodialysis, corrected serum calcium ≥8.3 mg/dL, and previous treatment/contraindication with generic vitamin D analogs. Claims will be denied without proper prior authorization.